Largest Pharma Companies in the World (2026 Revenue Rankings)
The largest pharma companies in the world play a central role in global healthcare, developing blockbuster drugs for cancer, cardiovascular disease, immunology, vaccines, and metabolic disorders.
Boosted by a 45% increase in sales in 2025, Eli Lilly has become the fourth-largest company in the biopharma industry. The Indianapolis drugmaker increased its sales from $45 billion in 2024 to $65.2 billion last year, catapulting past Bristol Myers Squibb, Novartis, AstraZeneca, AbbVie, Pfizer and Merck in the rankings.
.png)
The largest pharma companies are defined not only by revenue, but by global scale, research investment, and therapeutic reach. These companies typically:
• Spend tens of billions annually on R&D
• Operate across the U.S., Europe, and emerging markets
• Control multiple blockbuster drug franchises
• Influence global drug pricing and treatment standards
As a result, the biggest pharmaceutical companies continue to shape the future of medicine, particularly in oncology, immunology, obesity, and chronic disease management.
2026 Top 20 Pharma Revenue & Market Cap Leaderboard
| Rank | Company | Ticker | HQ / Country | FY2025 Revenue | YoY Growth | Market Cap (Aug 2026) |
|---|---|---|---|---|---|---|
| 1 | Johnson & Johnson | NYSE: JNJ | USA | $94.2B | +6.0% | ~$620B |
| 2 | Sinopharm Group* | HKEX: 1099 | China | ~$80.0B (RMB 575.2B) | ~flat | ~$8.3B |
| 3 | Roche | SIX: ROG | Switzerland | ~$70B (CHF 61.5B) | +7% CER | ~$370B |
| 4 | Eli Lilly | NYSE: LLY | USA | $65.2B | +45% | ~$1.12T |
| 5 | Merck & Co. (MSD) | NYSE: MRK | USA | $65.0B | +1% | ~$322B |
| 6 | Pfizer | NYSE: PFE | USA | $62.6B | -2% | ~$150B |
| 7 | AbbVie | NYSE: ABBV | USA | $61.2B | +8.6% | ~$446B |
| 8 | AstraZeneca | NASDAQ: AZN | UK | $58.7B | +9% CER | ~$300B |
| 9 | Novartis | NYSE: NVS | Switzerland | $54.5B | +8% cc | ~$300B |
| 10 | Bristol Myers Squibb | NYSE: BMY | USA | $48.2B | Flat | ~$130B |
| 11 | Sanofi | NASDAQ: SNY | France | ~$47.5B (€43.6B) | +9.9% CER | ~$120B |
| 12 | Novo Nordisk | NYSE: NVO | Denmark | $43.3B | +10% CER | ~$210B |
| 13 | GSK | NYSE: GSK | UK | ~$42.8B (£32.7B) | +7% CER | ~$123B |
| 14 | Amgen | NASDAQ: AMGN | USA | $36.8B | +10% | ~$196B |
| 15 | Boehringer Ingelheim* | Private | Germany | ~$30.3B (€27.8B) | +7.3% | Private |
| 16 | Gilead Sciences | NASDAQ: GILD | USA | $29.4B | +2% | ~$178B |
| 17 | Takeda Pharmaceutical** | NYSE: TAK | Japan | ~$29.2B | ~flat | ~$55B |
| 18 | Teva Pharmaceutical | NYSE: TEVA | Israel | $17.3B | +4.3% | ~$38B |
| 19 | Regeneron Pharmaceuticals | NASDAQ: REGN | USA | $14.3B | +1% | ~$82B |
| 20 | Astellas Pharma** | NYSE: ALPMY | Japan | ~$13.5B | +varies | ~$29B |
↔ Swipe the table sideways to see all columns on mobile.
*Sinopharm Group is primarily a pharmaceutical and medical-device distributor/wholesaler rather than an R&D-driven manufacturer (see note below); Boehringer Ingelheim is privately held and discloses no market capitalization. **Takeda and Astellas report on a fiscal year ending March 31; figures reflect the closest comparable 12-month period to calendar 2025. Non-U.S.-dollar FY2025 figures are approximate conversions using average 2025 exchange rates. Market caps are approximate as of early August 2026 and fluctuate daily — verify against a live data source before use in investment decisions.
Q2 2026 Earnings Roundup
Calendar-Q2 2026 earnings season ran from late July through early August 2026, and it was a broadly strong one for Big Pharma: six of the top ten companies by revenue raised full-year guidance. Here's what moved:
- Johnson & Johnson — Q2 revenue rose 6.6% to $25.31 billion, with Innovative Medicine up 7.8% to $16.38 billion (Tremfya +72.5% to $2 billion). J&J raised full-year 2026 guidance to $100.8–101.4 billion in reported sales (midpoint $101.1 billion) and adjusted EPS of $11.60–11.75.
- Eli Lilly — Q2 revenue soared 47.7% year-over-year to $22.97 billion, with adjusted EPS of $8.38 beating consensus by 27%. Management raised full-year 2026 revenue guidance to $85–87 billion, and the stock rallied on the print — pushing market cap to roughly $1.12 trillion.
- Merck & Co. — Q2 revenue climbed 5% to $16.6 billion, beating consensus, with newly launched products more than doubling to $1.5 billion. Merck raised and narrowed full-year 2026 guidance to $66.3–67.3 billion, even while absorbing a $2.31-per-share charge tied to its $6.8 billion acquisition of Terns Pharmaceuticals.
- Pfizer — Q2 revenue reached $15.03 billion, with non-COVID revenue up 18% operationally. Pfizer raised the midpoint of full-year 2026 guidance by $500 million to $60.5–62.5 billion, unveiled $2.5 billion in additional 2027–2029 cost savings, and closed its Innovent Biologics transaction in July.
- AbbVie — Q2 revenue grew 10.2% to $16.99 billion. Skyrizi ($5.5 billion, +24%) and Rinvoq ($2.5 billion, +23.7%) keep outpacing Humira's decline. AbbVie raised full-year 2026 revenue guidance to roughly $67.6 billion and announced a planned acquisition of Apogee Therapeutics to bolster its dermatology and respiratory immunology pipeline.
- Novo Nordisk — Q2 adjusted sales grew 7% at constant exchange rates to DKK 78.5 billion. Management raised full-year 2026 guidance for the second time this year, to 0% to -6% adjusted growth (from -4% to -12%, itself an improvement on the -5% to -13% guidance that triggered a sharp February 2026 stock selloff). The oral Wegovy pill has now surpassed 5 million cumulative U.S. prescriptions, though U.S.-listed shares still fell after the print on continued pricing pressure.
- GSK — Core operating profit rose 7% in Q2 2026, extending the momentum from its FY2025 oncology and HIV franchise growth.
Largest Pharma Companies by Revenue (Global Ranking): Company-by-Company Breakdown
1. Johnson & Johnson — $94.2 Billion
Johnson & Johnson posted full-year 2025 reported sales growth of 6.0% to $94.2 billion, according to its Q4 and full-year 2025 results. Oncology grew 22% on Innovative Medicine, with Darzalex crossing $14.3 billion and Carvykti nearly doubling to $1.9 billion, while Stelara biosimilar erosion cut Immunology revenue by roughly $4.3 billion. MedTech contributed $33.8 billion. J&J guided to $100–101 billion in 2026 revenue, crossing $100 billion for the first time, and its market cap sat at roughly $600 billion in mid-2026.
Johnson & Johnson has gotten comfortable holding down the top spot on this report over the years. But even J&J’s decision to spin off its consumer healthcare unit in recent years hasn't been enough to knock the pharma powerhouse off.Johnson & Johnson’s pharma and medtech units delivered $94.2 billion in sales last year, an impressive 6.1% increase from $88.8 billion the prior year. The growth came from several key products, including J&J’s leading multiple myeloma offerings, its depression nasal spray Spravato, anticoagulant Xarelto and several other medicines.
Besides its own offerings, J&J has been relatively active on the M&A front in recent years. Last year, this materialized with the company’s acquisition of Intra-Cellular Therapies and its promising schizophrenia and bipolar treatment Caplyta. Shortly after the buyout, Caplyta scored a major label expansion as an add-on treatment for major depressive disorder. All told, the drug generated $700 million in revenue last year.
Elsewhere, the company’s medtech unit remains a major contributor, with its sales reaching $16.4 billion last year.
With J&J’s leadership position in these two markets firmly established, the company is still stepping on the gas. J&J projects its 2026 sales will come in between $99.5 billion and $101.08 billion, suggesting the $100 billion mark is comfortably within its sights.
The upward revenue trajectory comes despite Johnson & Johnson spinning off its consumer health unit, Kenvue, in 2023. The strategic move, intended to sharpen J&J’s focus on innovative products, has hardly slowed the company’s momentum, as it has managed to post revenue growth of 4% or more in recent years.
As for headwinds, J&J expects near-term generic and biosimilar erosion for pulmonary arterial hypertension drug Opsumit and immunology blockbuster Simponi. The drugs pulled down more than $2.8 billion in the U.S. in 2025, making them meaningful contributors but not completely calamitous when they tumble over the patent cliff.
Price to earnings Ratio (TTM*): 29.86
2. Sinopharm Group — ~$80.0 Billion (RMB 575.2 Billion)
Sinopharm Group, a core subsidiary of China National Pharmaceutical Group (Sinopharm/CNPGC) listed on the Hong Kong Stock Exchange, reported 2025 group revenue of RMB 575.2 billion, roughly $80 billion, according to its official investor relations disclosures. Sinopharm is China's largest wholesaler and retailer of drugs and medical devices, serving more than 700,000 institutional customers nationwide, with pharmaceutical distribution making up over 70% of revenue and medical device distribution and retail pharmacy (including the Guoda Drugstore chain) contributing the remainder. Despite its enormous top line, Sinopharm's market capitalization is only around $8.3 billion, reflecting the thin margins typical of pharmaceutical distribution and wholesale businesses rather than the high-margin, IP-driven economics of drug manufacturers.
Readers researching this ranking should understand an important structural distinction: Sinopharm Group is a pharmaceutical and medical-device distributor — the Chinese equivalent of McKesson or Cardinal Health in the U.S. — not an R&D-driven drug manufacturer like the other 19 companies on this list. Sinopharm buys, warehouses, and resells medicines and devices made by thousands of manufacturers (domestic and international) through a nationwide logistics network, earning thin distribution margins on enormous transaction volume. That business model explains why Sinopharm's ~$80 billion in revenue would rank it second on this list by top-line sales alone, yet its market capitalization of roughly $8.3 billion is smaller than that of companies with a fraction of its revenue, such as Regeneron ($14.3 billion in revenue, ~$82 billion market cap). Investors and researchers comparing "pharma company size" should treat revenue-based rankings that include distributors like Sinopharm separately from R&D-intensive manufacturer rankings, since profit margins, innovation pipelines, and patent economics are not comparable across the two business models.
Related: In June 2026, China approved satricabtagene autoleucel (satri-cel; CT041), making it the first CAR-T cell therapy to receive regulatory approval for a solid tumor.
3. Roche — ~$70 Billion (CHF 61.5 Billion)
Roche reported group sales of CHF 61.5 billion for 2025, up 7% at constant exchange rates (2% in Swiss francs, reflecting a strong franc). The Pharmaceuticals Division grew 9% CER to CHF 47.7 billion, led by five core growth drivers — Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo — which together added CHF 21.4 billion. Xolair was the standout at +32% on a new food-allergy indication. Roche has declared an ambition to become a top-3 global obesity company by 2030 and reported competitive Phase 2 obesity data for its candidate CT-388 in early 2026.
4. Eli Lilly and Company — $65.2 Billion
Eli Lilly delivered the industry's standout year, with revenue of $65.2 billion, up 45%, per its Q4 2025 earnings release. Mounjaro nearly doubled to $23.0 billion and Zepbound surged 175% to $13.5 billion, together delivering $36.5 billion — more than the entire annual revenue of Gilead or Amgen. Lilly's oral GLP-1 pill orforglipron (branded Foundayo) won FDA approval in April 2026. The company's market cap crossed $1 trillion in November 2025 and stood at roughly $1.1 trillion by July 2026, making it the world's most valuable healthcare company by a wide margin, with 2026 guidance of $80–83 billion in revenue.
As the market for branded obesity medications has continued to flourish, Eli Lilly has steadily ramped up pressure on first-comer and chief competitor Novo Nordisk, with its 2025 performance reflecting Lilly’s strong position in current GLP-1 prescription trends, particularly in the U.S.Now, Lilly is telegraphing a repeat performance from its dual GIP/GLP-1 blockbusters for diabetes and obesity, Mounjaro and Zepbound, and projecting even greater sales highs in 2026 on the back of a closely watched obesity pill launch.
Still, the halo around the Indianapolis drugmaker can’t last forever, and at least one analyst has pointed to the potential for cracks to start forming this year. Meanwhile, as both Lilly and Novo work to line up successors to their commercial incretin drug empires, a new front in the obesity contest is opening in 2026 with the launch of the companies’ respective oral GLP-1s, where Lilly’s dominance is less assured.
Lilly’s full-year sales climbed an impressive 45% to more than $65 billion in 2025, with Mounjaro and Zepbound—plus the company’s breast cancer therapy Verzenio—doing the bulk of the heavy lifting.
In fact, tirzepatide proved the world’s best-selling drug last year, with its sales also eclipsing those of Merck’s megablockbuster cancer med Keytruda in 2025.
That stellar performance reflects Lilly’s growing edge over Novo in recent years, as well as how innately tied the company’s current fortunes are to Mounjaro and Zebpound.
That demand earned Lilly the distinction of becoming the first drugmaker to reach a $1 trillion market valuation back in November 2025—an elite merit often reserved for tech giants.
Lilly’s shares took a bit of a dive in March 2026, when investment Bank HSBC downgraded the drugmaker’s stock, accompanied by a note from analyst Rajesh Kumar warning of pricing pressures, increasing obesity market competition and “potential for disappointment” with the critical launch of Lilly’s GLP-1 pill for weight loss, orforglipron, which was approved by the FDA as Foundayo on April 1.
Lilly doesn’t appear to have quite the same level of concern, and many other analysts now seem buzzy about Foundayo’s launch prospects following the drug’s FDA nod.
For 2026, the company forecasts sales between $80 billion and $83 billion, with the midpoint of that range good for a 25% increase over Lilly’s 2025 sales haul. If that pace of growth nevertheless seems muted compared to Lilly’s climb last year, it could be attributed to pricing, which is “expected to be a drag on growth in the low- to mid-teens,” the company’s CFO, Lucas Montarce, said on an investor call earlier this year.
A key drug-pricing deal with the White House last year, considerations on its direct-to-patient sales platform and coverage of Mounjaro for type 2 diabetes in China are all expected to weigh on price projections for tirzepatide this year, the executive explained.
Q2 2026 update: Lilly's Q2 2026 results, released August 5, showed revenue up 47.7% year-over-year to $22.97 billion and adjusted EPS of $8.38 — beating consensus by roughly 27%. Management raised full-year 2026 guidance to $85–87 billion, and the stock jumped nearly 5% on the print. Market cap sat at approximately $1.12 trillion in early August 2026, keeping Lilly the world's most valuable healthcare company by a wide margin. A drug-pricing deal struck with the White House in 2025 and Chinese Mounjaro coverage for type 2 diabetes remain the main variables management flags as pricing headwinds for tirzepatide going forward.
- 5-Yr performance: +352% | P/E (TTM): ~39.7
- Market capitalization: 1.08 T USD (TradingView)
- Price to earnings Ratio (TTM): 39.7
- 5 -Yr Performance: +352%
5. Merck & Co. (MSD outside the U.S. and Canada) — $65.0 Billion
Merck's total worldwide sales reached $65.0 billion in 2025, up 1%, according to its full-year 2025 results. Keytruda (pembrolizumab) grew 7% to $31.7 billion and now represents roughly 49% of total revenue, intensifying pressure to diversify ahead of its approximately 2028 patent cliff. Gardasil fell 39% to $5.2 billion on weak China and Japan demand, while newer launches Winrevair ($1.4 billion) and Capvaxive ($759 million) are emerging as diversification pillars. Merck's 2026 guidance of $65.5–67.0 billion came in below Street estimates.
In the golden days of the world’s top-selling pharmaceutical product, Keytruda, it would stand to reason that Merck would be one of the faster-growing companies in the industry. But that was before the stunning implosion of Gardasil.
The vaccine, which helps prevent diseases linked to the human papillomavirus (HPV), was on a juggernaut trajectory for its first decade on the market. But in 2024, sales suddenly stalled, largely attributed to a demand issue in China, with local companies bringing cheaper alternatives to the market.
Last year, the issue spread to Japan, the company said. After a 3% decline in Gardasil in 2024, the shortfall hit with full force in 2025, as Gardasil sales fell from $8.6 billion to $5.2 billion, for a 39% drop-off.
This year, a sales slide for Gardasil is likely in the U.S. as well, as the CDC has adjusted its recommendation for HPV shots from two or three doses for children ages 11-12 to a single dose. Jefferies analyst Akash Tewari said in January that the new directive could cost the company between $315 million and $630 million in sales in 2026.
The Gardasil free fall accompanied a slowdown in growth for Keytruda, with sales increasing from $29.5 billion in 2024 to $31.7 billion. The 7% increase in 2025 came after growth of between 18% and 22% each of the previous four years.
This year, with Gardasil’s decline expected to level off, the company is guiding to a revenue window of $65.5 billion to $67 billion. At the midpoint, it would be a 2% growth in revenue for 2026.
Even with Keytruda accounting for 49% of Merck’s revenue in 2026—and the company expecting to lose its patent protection for the cancer powerhouse in December 2028—it still is projecting overall revenue will reach $70 billion by the middle of the next decade.
To accomplish this feat, Merck’s business development initiatives will have to pan out. One that has, so far, is its $11.5 billion buyout of Acceleron in 2021, which brought in the pulmonary arterial hypertension drug Winrevair, the company’s newest blockbuster, with sales reaching $1.4 billion in 2025.
In 2024, Merck acquired Verona for $10 billion to gain the chronic obstructive pulmonary disease (COPD) blockbuster Ohtuvayre and spent $9.2 billion on Cidara Therapeutics, targeting its antiviral, non-vaccine alternative for protection against influenza. In March of this year, Merck ponied up $6.7 billion for Terns and its prized leukemia candidate TERN-701.
During Merck’s fourth quarter conference call, CEO Rob Davis took exception to a questioner who asked if it will be “a company that grows modestly in good times and significantly pressured in less good times.”
“I am not sure I agree with your characterization that we will be a modest growing company in every year or less, depending on what happens. That is, I think, taking one year out of context,” Davis said. “Our belief in our ability to have sustainable growth once we get past the LOE [of Keytruda] is as high as it has ever been.”
Related:
- Moderna Merck Cancer Vaccine Phase 3 Results 2026: Intismeran Breakthrough + Social Media Reactions Explained (August 2026)
- Keytruda (Pembrolizumab): 25 Landmark KEYNOTE Trials That Changed Cancer Treatment (2026)
6. Pfizer — $62.6 Billion
Pfizer's 2025 revenue came in at $62.6 billion, down roughly 2%, as COVID-19 products Comirnaty and Paxlovid continued to normalize (combined ~$6.8 billion versus ~$13.1 billion in 2024). Ex-COVID revenue grew 6% operationally, led by Abrysvo, Padcev, and a fast-growing oncology biosimilars business. Pfizer absorbed $4.4 billion in non-cash pipeline impairments in Q4 and has re-entered the obesity category through its 2025 Metsera acquisition. 2026 guidance of $59.5–62.5 billion implies continued softness from loss-of-exclusivity events.
The past few years for Pfizer have reflected both high highs and low lows as the company’s COVID-19 products reacted to inconsistent demand. As for the company’s other vaccines, respiratory syncytial virus vaccine Abrysvo was negatively impacted by narrowed vaccine recommendations from the Centers for Disease Control and Prevention. The agency flipped on its previous recommendation for all adults aged 60 and older to instead recommend the vaccine for people 75 years and older and those aged 60 to 74 with a higher risk of severe disease. A decline in vaccination rates due to the shrunken U.S. market played a part in Abrysvo sales falling 62% during 2024’s fourth quarter, Pfizer said, although the shot picked up $890 million in yearly sales.
Meanwhile, Pfizer’s long-dominant pneumococcal vaccine franchise, Prevnar, saw relatively flat sales over the year but could face trouble on the horizon with Merck and its 21-serotype Capvaxive eager to edge in on Prevnar’s turf.
7. AbbVie — $61.2 Billion
AbbVie reported net revenues of $61.2 billion, up 8.6%, successfully completing its post-Humira transition. Skyrizi ($17.56 billion, +50%) and Rinvoq ($8.30 billion, +39%) together generated $25.9 billion, clearing management's 2027 combined-sales target of $27 billion two years early, while Humira continued its decline to $4.54 billion (down from $9.0 billion in 2024). AbbVie's aesthetics segment (Botox Cosmetic, Juvederm) softened, but the company still guided to approximately $67 billion in 2026 revenue.
8. AstraZeneca — $58.7 Billion
AstraZeneca's 2025 revenue reached $58.7 billion, up roughly 9% CER, with oncology contributing $25.6 billion (+14%), or 44% of product revenue, across 16 blockbuster medicines. Imfinzi grew 29% to about $6.1 billion, and AstraZeneca's share of Enhertu (partnered with Daiichi Sankyo) rose 46% to $2.8 billion (roughly $5.2 billion combined globally). In January 2026, AstraZeneca entered an up-to-$18.5 billion partnership with China's CSPC Pharmaceutical for next-generation obesity and diabetes assets, marking its formal entry into the GLP-1 category.
9. Novartis — $54.5 Billion
Novartis, now a pure-play innovative medicines company, reported 2025 revenue of $54.5 billion, up about 8% constant currency, and hit its 40% core operating margin target two years ahead of plan. Heart failure drug Entresto lost U.S. exclusivity in 2025, but breast cancer drug Kisqali grew 57% to $4.8 billion, with Kesimpta (+36%) and Scemblix (+85%) also inflecting strongly. Novartis has flagged 2026 as its highest generic-erosion year in company history.
10. Bristol Myers Squibb — $48.2 Billion
Bristol Myers Squibb's 2025 revenue was roughly flat at $48.2 billion, as its Growth Portfolio overtook Legacy products for the first time, reaching $26.4 billion (+17%) or 55% of total revenue. Eliquis remained resilient at $14.4 billion (+8%), and newer launches Breyanzi (+82%) and Camzyos (+77%) both crossed $1 billion, offsetting a 49% collapse in Revlimid to $3.0 billion as generic competition intensified. BMS guided to $46.0–47.5 billion in 2026 revenue as its Legacy portfolio continues to decline.
11. Sanofi — ~$47.5 Billion (€43.6 Billion)
Sanofi delivered net sales of €43.63 billion, up 9.9%, its strongest growth in years following the divestment of its Opella consumer-health unit. Dupixent, co-developed with Regeneron, generated €15.7 billion (+25.2%), now about 36% of total sales, while newer hemophilia therapy Altuviiio reached blockbuster status at €1.16 billion in its first full year. Sanofi has redeployed Opella proceeds into acquisitions including Blueprint Medicines and, pending close, Dynavax.
12. Novo Nordisk — $43.3 Billion
Novo Nordisk closed a turbulent 2025 with net sales of roughly $43.3 billion (DKK 309 billion), up about 10% at constant exchange rates but only around 4% as reported. Ozempic remained the top product at DKK 127.1 billion, and Obesity Care sales grew 31% CER to DKK 82.3 billion, but a shocking 2026 guidance of -5% to -13% adjusted CER growth triggered an 18% single-day stock decline in February 2026 — the sector's most dramatic reaction of the earnings season. The year also brought a new CEO (Maziar Mike Doustdar), roughly 9,000 job cuts, and the U.S. launch of an oral Wegovy pill in January 2026.
13. GSK — ~$42.8 Billion (£32.7 Billion)
GSK delivered turnover of £32.7 billion, up 7% CER, driven by oncology sales surging 43% (Jemperli nearly doubled) and HIV portfolio growth of 11%, including long-acting therapies Cabenuva and Apretude, up a combined 46%. GSK secured five FDA approvals in 2025 and guided to 3–5% CER turnover growth for 2026.
14. Amgen — $36.8 Billion
Amgen grew revenue 10% to $36.8 billion, with 14 products exceeding $1 billion in annual sales. Repatha surged 36% to $3.0 billion on new cardiovascular outcomes data, and Tezspire grew 52% to $1.5 billion, while Enbrel continued to decline (-33%) from biosimilar erosion. Amgen's most closely watched pipeline asset, obesity candidate MariTide, has six Phase 3 studies underway with results expected in 2026.
15. Boehringer Ingelheim — ~$30.3 Billion (€27.8 Billion)
Boehringer Ingelheim, the largest privately held pharmaceutical company in the world, reported group net sales of €27.8 billion, up 7.3%, spanning its Human Pharma and Animal Health divisions. Key products include cardio-renal-metabolic drug Jardiance and pulmonary fibrosis treatment Ofev, alongside two new 2025 launches: lung cancer drug Hernexeos and pulmonary fibrosis therapy Jascayd. Family- and foundation-controlled since 1885, Boehringer discloses no public market capitalization.
16. Gilead Sciences — $29.4 Billion
Gilead's revenue grew 2% to $29.4 billion, anchored by Biktarvy's HIV dominance ($14.3 billion, +7%, over 52% U.S. market share) and Descovy's 31% growth on PrEP demand. The company faced oncology pipeline setbacks, including a Phase 3 failure for Trodelvy in first-line breast cancer, but continues to expand its HIV franchise toward the 2040s with no near-term patent cliff.
17. Takeda Pharmaceutical — ~$29.2 Billion
Takeda, reporting on a fiscal year ending March 31, guided to approximately JPY 4.3 trillion (roughly $29 billion) in revenue for the period closest to calendar 2025. Entyvio remains the anchor franchise at roughly $4.8 billion for the first nine months, while Vyvanse/Elvanse generic erosion (-46%) has been the dominant headwind. Takeda has flagged three potential multibillion-dollar launches over the next 18 months: oveporexton (narcolepsy), rusfertide (polycythemia vera), and zasocitinib (a TYK2 inhibitor).
18. Teva Pharmaceutical Industries — $17.3 Billion
Teva, the world's largest generic drug manufacturer, reported 2025 net revenues of $17.3 billion, up from $16.5 billion in 2024, according to its SEC filings. Growth was driven by innovative products including Austedo (tardive dyskinesia) and Ajovy (migraine), alongside a resilient generics and biosimilars base. Teva continues executing its "Pivot to Growth" strategy targeting a 30% operating margin, with roughly $700 million in net savings targeted by 2027.
19. Regeneron Pharmaceuticals — $14.3 Billion
Regeneron's company-booked revenue grew only 1% to $14.3 billion, masking the continued strength of Dupixent (global sales of $17.8 billion, +26%, booked primarily by partner Sanofi) because Regeneron's own EYLEA franchise fell 27% to $4.39 billion combined (EYLEA plus EYLEA HD) amid new aflibercept biosimilar competition. Regeneron did not provide specific 2026 revenue guidance.
20. Astellas Pharma — ~$13.5 Billion
Astellas, also reporting on a fiscal year ending March 31, delivered an operational turnaround highlighted by a 52% Q3 EPS beat and a third consecutive upward guidance revision. Prostate cancer drug Xtandi remains the anchor at a forecast ~$6.1 billion for the fiscal year, while five newer strategic brands — led by Padcev (+39%) and Vylay (+831% from a small base) — collectively grew 45%.
Key 2026 Growth Drivers: GLP-1, Oncology & Immunology
- GLP-1 / metabolic drugs: Eli Lilly's Mounjaro and Zepbound ($36.5B combined) and Novo Nordisk's Ozempic and Wegovy remain the industry's largest growth category. New entrants are piling in: AstraZeneca's $18.5B CSPC partnership, Amgen's MariTide, Roche's CT-388, and Pfizer's Metsera-derived pipeline all signal a crowded obesity market by 2027–2028.
- Oncology: Merck's Keytruda ($31.7B), J&J's Darzalex ($14.3B), AstraZeneca's Imfinzi (~$6.1B) and Enhertu (~$5.2B combined with Daiichi Sankyo), and Novartis's Kisqali ($4.8B) anchor immuno-oncology, even as Keytruda's 2028 patent cliff drives sector-wide diversification into antibody-drug conjugates and cell therapies.
- Immunology: AbbVie's Skyrizi and Rinvoq ($25.9B combined) and Sanofi's Dupixent (€15.7B) show how post-patent-cliff franchises can outgrow the blockbusters they replaced.
- Generics and distribution: Teva's steady generics/biosimilars base and Sinopharm's vast Chinese distribution network illustrate that industry scale isn't only built through novel drug discovery.
Frequently Asked Questions
Which pharmaceutical company has the highest revenue in 2026?
Johnson & Johnson, with $94.2 billion in full-year 2025 revenue, up 6.0% year-over-year.
Where does Sinopharm Group rank among global pharmaceutical companies?
By revenue alone, Sinopharm's roughly $80 billion (RMB 575.2 billion) would place it second on this list, but as a distributor rather than an R&D-based drug manufacturer, it is not directly comparable to the other companies ranked here.
Which pharma company has the highest market capitalization?
Eli Lilly, at roughly $1.1 trillion as of August 2026 — the first health-care company ever to cross the trillion-dollar mark.
What is the fastest-growing top pharmaceutical company by revenue?
Eli Lilly, up 45% to $65.2 billion in 2025, driven by Mounjaro and Zepbound.
Which pharmaceutical companies are privately held?
Boehringer Ingelheim, with roughly $30 billion in 2025 net sales, is the largest privately held pharmaceutical company in the world and has no public market capitalization.
Methodology
- This ranking is based on each company's audited or company-reported full-year 2025 consolidated revenue as disclosed in official earnings releases and regulatory filings between January and March 2026.
- Figures reported in non-U.S. currencies (Swiss francs, euros, British pounds, Danish kroner, Chinese renminbi) are converted to approximate U.S. dollars using average 2025 exchange rates and are labeled accordingly.
- Takeda and Astellas report on a fiscal year ending March 31, so their figures reflect the nearest comparable 12-month period rather than the calendar year.
- Sinopharm Group's revenue reflects its distribution/wholesale business model and is not directly comparable to R&D-driven pharmaceutical manufacturers (see the dedicated note above).
- Market capitalization figures are approximate, reflect trading data from June through early August 2026, and fluctuate daily; verify against a live data source before use in investment decisions.
Read More:
- Top 10 Drug Launches & Patent Cliffs (2026 Update): 2025's Full-Year Scorecard
- Top 10 Pharma Companies by R&D Spend: Rankings & Pipeline Strategy
Conclusion
The largest pharma companies in the world occupy a unique position in global healthcare. Their scale allows them to fund multi-billion-dollar research programs, navigate complex regulatory environments, and deliver medicines across virtually every major therapeutic area. While smaller biotech firms often drive early innovation, it is the biggest pharmaceutical companies that ultimately determine which therapies reach global patients at scale.
As this ranking shows, revenue leadership in 2026 reflects more than commercial success. It signals sustained investment in oncology, immunology, metabolic disease, vaccines, and chronic care—areas that continue to shape treatment standards worldwide. At the same time, these companies face mounting challenges, including patent expirations, biosimilar competition, and pricing reforms, forcing even the largest players to adapt their pipelines and business models.
However, healthcare is no longer a single investment sector. Most investors still treat “healthcare” as synonymous with big pharma. They load up on the usual large-cap pharmaceutical names and call it a day.
To find genuine gems, investors must adopt a broader perspective and conduct deeper dives into the rapidly expanding healthcare ecosystem. This ecosystem now includes pharmaceuticals, biotechnology, cell and gene therapy, digital health, medical tourism, longevity medicine, medical aesthetics, hospitals, diagnostics, immunotherapy, senior care, healthcare infrastructure — and the explosive GLP-1 / weight-loss & obesity treatment sector (17).
Disclaimer
The information presented in this article, is intended for general informational purposes only and should not be construed as professional financial, investment, or medical advice. The revenue figures, company rankings, and projections are based on publicly available data, company reports, and industry estimates as of 2026. All currency conversions, where applicable, are based on annual average exchange rates, and revenues outside the health sciences sector have been excluded for consistency.
While efforts have been made to ensure the accuracy and timeliness of the information, One Day Advisor and the article’s authors do not guarantee the completeness, reliability, or suitability of the content for any particular purpose. Readers are encouraged to verify details independently and consult qualified professionals before making any business, investment, or healthcare decisions based on the information provided.
The article may reference ongoing developments, regulatory actions, or market events that are subject to change. One Day Advisor is not responsible for any losses or damages arising from the use of this information.
- Top 10 Cancer Drug Companies (2026)
- Top 10 Health Insurance Companies
- Top 10 drugs losing US exclusivity in 2025
- Top 10 Drugs by Worldwide Sales in 2025
- Top 10 Cancer Fighting Supplements 2026
- Top 10 most anticipated drug launches of 2025
- China's Biotech Boom: A Catalyst for Shifting Global Investment Patterns
- Top Pharma ETFs for 2026: The Best Pharmaceutical Investments for Healthcare Growth
- Weight-loss drugs draw thousands of lawsuits alleging serious harm (USA Today Jan 2026)
- The top 20 pharma companies by 2024 revenue (FiercePharma Special Report 2025)
- The top 20 pharma companies by 2025 revenue (FiercePharma Special Report 2026)
- Big Pharma's 10 highest-paid CEOs of 2025 (FiercePharma Special Report 2026)
- Top 5 Emerging Biotech Hubs in 2026: Global Cities to Watch
- Healthcare Market Sub-Sectors vs. Annual Growth Rate: Where Is the Growth in 2026?
.png)
Comments